Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Slightly Bullish +20

ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential? - Zacks Investment Research

📈 ImmunityBio reported $113 million in net product revenues for 2025, representing a 700% year-over-year increase driven by repeat prescribing.

🔬 ImmunityBio is seeking FDA label expansion for Anktiva in BCG-unresponsive NMIBC and advancing studies in BCG-naïve patients.

🌍 ImmunityBio received its first regulatory approval for Anktiva in non-small cell lung cancer (NSCLC) in Saudi Arabia in January.

💊 Moderna plans to launch at least three new marketed products by 2028 to reduce reliance on declining COVID-19 vaccine demand.

🤝 Moderna is co-developing a personalized cancer therapy called intismeran autogene with Merck, targeting melanoma and NSCLC.

⚠️ ImmunityBio recently received an FDA warning letter for misleading promotional claims regarding Anktiva's efficacy.

📉 ImmunityBio faces execution risk due to its sole dependence on the single marketed drug Anktiva.

🧪 Moderna's experimental CMV vaccine failed in late-stage development, highlighting pipeline risks.

💰 ImmunityBio trades at a premium valuation with a forward price-to-sales ratio of 29.67x versus Moderna's 9.40x.

🛡️ Analysts conclude Moderna is the safer investment pick due to its diversified portfolio and financial flexibility.

Bullish Signals
  • ImmunityBio achieved a massive 700% year-over-year revenue growth in 2025, reaching $113 million in net product revenues.
  • Physician confidence in ImmunityBio's Anktiva is increasing, evidenced by strong repeat prescribing rates.
  • The ongoing BCG shortage creates a favorable market environment for ImmunityBio's combination therapy.
  • ImmunityBio is actively expanding its drug's indications beyond bladder cancer into lung and other difficult-to-treat cancers.
  • Moderna successfully transitioned from a loss-making clinical-stage company to one of the most profitable biotech firms in healthcare.
  • Moderna has secured over 30 mRNA-based investigational candidates, many in clinical development stages.
  • Moderna plans to launch multiple new products by 2028, including personalized cancer therapies and norovirus vaccines.
  • Moderna's partnership with Merck on intismeran autogene includes three pivotal phase III studies across melanoma and NSCLC.
Risk Factors
  • ImmunityBio faces significant execution risk due to its heavy reliance on a single marketed drug, Anktiva.
  • The FDA issued a warning letter to ImmunityBio for misleading promotional claims that overstated efficacy and omitted risks.
  • This regulatory scrutiny contributed to a substantial drop in ImmunityBio's stock price earlier in the week.
  • Moderna remains heavily reliant on COVID-19 vaccines, which are experiencing significant demand decline post-pandemic.
  • Moderna's RSV vaccine (mResvia) has struggled to gain market traction against established competitors like GSK and Pfizer.
  • Moderna faces increasing competitive pressure from large pharmaceutical players affecting its commercial performance.
  • The recent failure of Moderna's experimental CMV vaccine in late-stage development raises questions about pipeline execution.
Full Analysis
The article compares ImmunityBio (IBRX) and Moderna (MRNA) as investment options, highlighting their distinct business models. ImmunityBio relies heavily on its single marketed drug, Anktiva, which saw net product revenues surge to $113 million in 2025, driven by repeat prescribing and a BCG shortage. The company is pursuing label expansions for bladder cancer indications and exploring applications in lung, pancreatic, and other difficult-to-treat cancers, with regulatory discussions planned later this year. Moderna (MRNA), conversely, has transitioned from a clinical-stage biotech to a profitable commercial entity following its successful COVID-19 vaccine sales. The company aims to diversify beyond its declining pandemic-era revenue by launching at least three new products by 2028, including influenza, norovirus, and personalized cancer therapies co-developed with Merck. Moderna currently has over 30 investigational candidates in development, though it faces competitive pressure from large pharma players in the RSV vaccine market. Key risks for ImmunityBio include its dependence on a single drug, recent FDA scrutiny regarding misleading promotional claims that caused a stock price drop, and execution risks associated with its pipeline. Moderna faces challenges such as reliance on declining COVID-19 vaccine demand, competitive struggles with its RSV vaccine, and the inherent risk of late-stage clinical failures, exemplified by its experimental CMV vaccine setback. From a valuation perspective, ImmunityBio trades at a significant premium to Moderna, with a price-to-sales ratio of 29.67x compared to Moderna's 9.40x. Despite ImmunityBio's strong growth momentum, the analysis concludes that Moderna represents a safer investment pick due to its broader pipeline, financial flexibility from cost-saving initiatives, and better long-term visibility despite remaining challenges.